Add-on salmeterol versus montelukast in Arg/Arg-16 asthmatics

Completed

• Conditions: Asthma; Respiratory

• Registration Number: ISRCTN49849003
• Lead Sponsor: niversity of Dundee (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07-31
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

All children and adolescents (5 - 18 years, either sex) with asthma in Tayside (Scotland) known:
1. To carry the Arg/Arg-16 genotype, and
2. Currently on inhaled steroids, and
3. Inhaled bronchodilators according to need
Will be telephoned or contacted through home visits to establish if they have had:
1. Any school absences from asthma, or
2. Out-of-hours visits to General Practitioner (GP)/hospital visits or admissions due to asthma over the previous 12 months

Exclusion Criteria

The presence of serious respiratory or multi-system disease (e.g. cystic fibrosis, cancer under current treatment)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oral montelukast is associated with reduced school absences in comparison to inhaled salmeterol over a period of 1 year in Arg/Arg-16 asthmatic children.

Secondary Outcome Measures

Name	Time	Method
1. Oral montelukast is associated with reduced out-of hours visits/hospital visits or admissions in comparison to inhaled salmeterol over a period of 1 year <br>2. Oral montelukast is associated with a reduction in airway resistance in comparison to inhaled salmeterol over a period of 1 year <br>3. Oral montelukast is associated with reduced exhaled nitric oxide levels in comparison to inhaled salmeterol over a period of 1 year <br>4. Oral montelukast is associated with reduced salivary eosinophilic cationic protein levels in comparison to inhaled salmeterol over a period of 1 year <br>5. Oral montelukast is associated with improved asthma specific quality-of-life in comparison to inhaled salmeterol over a period of 1 year <br>6. Oral montelukast is associated with improved morning peak expiratory flow rate in comparison to inhaled salmeterol over a period of 1 year